Pharma Industry News
August 11th, 2009
A recent study proclaims that women who currently take, or have taken hormone therapy are at a greater risk of ovarian cancer then women who have never participated in hormone therapy.
August 11th, 2009
Sanofi-aventis recently publicized the release of an Expert Statement issued by a board of multidisciplinary, internationally acclaimed experts, which follows an in-depth evaluation of the recent publications of registry analyses with Lantus in Diabetologia.
August 11th, 2009
The National Heart, Lung and Blood Institute (NHLBI) has halted a clinical trial involving drug treatment tests for pulmonary hypertension in adults who suffer from sickle cell disease.
August 11th, 2009
Array BioPharma Inc. has recently notified the public of their Phase 1 favorable top-line data clinical trial, conducted with a group Type 2 diabetes patients and their small molecule glucokinase activator (GKA), ARRY-403
August 10th, 2009
Until recently, Doctors have been unable to help damaged heart tissue heal itself after experiencing a heart attack.
August 10th, 2009
Researchers examine preliminary discoveries that possibly suggest that as a result of the 9/11 attack on the American Twin Towers, responders may be at an increase for risk of cancer of the blood: multiple myeloma.
August 10th, 2009
A new study has discovered that low dose radiation treatment for low-grade brain tumors can generate a continuous decline in cognitive functioning.
Treatment solutions for the most common kinds of brain tumors - low-grade gliomas, is radiation.
August 10th, 2009
A new study has proven that it is possible to preserve the fertility of a young woman diagnosed with early stage ovarian cancer, without compromising her survival; the solution is to save the woman’s uterus or ovary.
August 10th, 2009
Margaret A. Hamburg M.D., commissioner of the US FDA recently announced her obligation to “prevent harm to the American people” through immediate, dynamic, potent administration of FDA laws and rules.
August 10th, 2009
The US FDA recently issued a recommendation advising that certain pharmaceutical components used in the production or composition of drug products should be tested for melamine.
